Consistently, phosphorylated ERK1/2 was reduced upon loss or inactivation of SMYD3 in the orthotopic xenograft tumors (Fig. 4E), suggesting that SMYD3-catalyzed methylation of MAP3K2 promotes persistent activation of the MEK/ERK pathway in PCa cell lines and tumors. The gene discussed is MAPK3; the disease is posterior cortical atrophy.